https://www.dolcera.com/wiki/api.php?action=feedcontributions&user=Shobhit.pareek&feedformat=atomDolceraWiki - User contributions [en]2024-03-28T17:27:55ZUser contributionsMediaWiki 1.24wmf12https://www.dolcera.com/wiki/index.php?title=Template_-_Production_Of_Therapeutic_Glycoproteins&diff=9987Template - Production Of Therapeutic Glycoproteins2011-11-21T13:32:43Z<p>Shobhit.pareek: </p>
<hr />
<div>=Objective=<br />
* The objective is to create a technology landscape report in the area of "Production of Therapeutic Glycoproteins" <br /><br />
<br />
'''Comment''' <br /><br />
The idea is to find out the innovative market players in this technology area, those are the players that are the most technologically advanced in the market place. '''Intellectual Property''' that these players hold is taken as a measure of their technological prowess in this particular area. We have used Patents to point out the innovative and technologically advanced market players.<br />
<br />
=Table of Contents=<br />
<br />
1. Introduction<br><br />
1.1. Glycosylation<br><br />
1.2. Importance of Glycosylation in Therapeutic Proteins<br><br />
1.3. Glycosylation and Biopharmaceutical Manufacturing<br><br />
1.4. Glycosylation in Biosimilars<br><br />
2. Search Strategy<br><br />
3. Sample patent analysis<br><br />
4. Taxonomy<br><br />
5. Top Citations<br><br />
5.1. Patent Ranking<br><br />
5.2. Top Cited Patents<br><br />
6. Patent to product mapping<br><br />
7. Key Findings<br><br />
7.1. Major Player<br><br />
7.2. IP Activity<br><br />
7.2.1. IP Activity based on Publication year<br><br />
7.2.2. IP Activity based on Priority year<br><br />
7.3. Geographical Activity<br><br />
7.3.1. Geographical Activity of Patents & their Family members<br><br />
7.4. Categorization on the basis of production methods<br><br />
7.4.1. Mammalian cell lines<br><br />
7.4.2. Transgenic Animals<br><br />
7.4.3. Plants<br><br />
7.4.4. Microorganisms<br><br />
7.4.5. Enzymes<br><br />
7.4.6. Chemical/Cell free synthesis<br><br />
7.4.7. Fermentation/culture conditions<br><br />
8. Conclusion<br><br />
9. References<br><br />
10. Appendix A: Control patents<br><br />
11. Appendix B: Relevant class code definitions<br><br />
12. Appendix C: Concept table<br><br />
13. Appendix D: Search strategy<br />
<br />
=Methodology=<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|'''Search Strategy'''<br />
|1. Various keywords are retrieved for conducting the search related to production of therapeutic glycoproteins from pubmed mesh, relevant patents, scientific articles and thesaurus.<br>2. The database used for patent search is Thomson innovation.<br />
|-<br />
|align = "center" bgcolor = "#4F81BD"|'''Keywords'''<br />
|Glycosylation, therapeutic proteins, monoclonal antibody, hormone, production, cell culture, fermentation etc.<br />
|-<br />
|}<br />
<br />
=Introduction=<br />
<br />
'''Glycosylation:'''<br />
<br />
Post-translational modifications – and in particular glycosylation – play a decisive role in ensuring proper protein function. Glycosylation has been found to occur in a large variety of protein classes, including – but not limited to – antibodies, protein hormones, growth factors, cytokines and vaccines. Glycosylation is the covalent attachment of a carbohydrate component to the polypeptide backbone. For some proteins glycosylation can increase solubility, influence biological half-life and/or biological activity. The two main classes of glycosidic bonds to polypeptide chains are termed N-linked and O-linked.<br><br />
* '''N-linked glycosylation''': <font color="#231F20">the glycan is linked to nitrogen in the side chain of asparagine. The oligosaccharide is attached via the amide nitrogen of an asparagine residue in the consensus sequence "asparagine — any amino acid except proline — serine/ threonine"</font><br />
* '''O-linked glycosylation''': the glycan is linked to oxygen in the side chain of mostly serine or threonine, as well as hydroxylysine. No specific consensus sequence has been identified for O-linked glycosylation.<br />
<br />
<font color="#231F20">In the case of humans, the oligosaccharides are typically composed of the following monosaccharides: mannose (Man), glucose (Glc), N-acetylglucosamine (GlcNAc), fucose (Fuc), galactose (Gal), N acetylgalactosamine (GalNAc), and sialic or neuraminic acids. The monosaccharides are linked together in a linear or branching fashion via either α- or β-glycosidic bonds between specific carbon atoms of the individual monosaccharides.</font>[http://www.ncbi.nlm.nih.gov/pubmed/17033665 Walsh G et al, Nature Biotechnology,2006]<br />
<br />
'''Importance of Glycosylation in Therapeutic Proteins:'''<br />
<br />
Many important therapeutic proteins are glycosylated including epoetin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF) and tissue plasminogen activator (t-PA). Following table lists glycosylated therapeutics currently on the market.<br />
[[Image:Glycosylation 1.jpg|thumb|center|900px| '''List of Glycosylated Therapeutic Proteins''' Hossler P et al, Glycobiology,2009 [http://www.ncbi.nlm.nih.gov/pubmed/19494347]]]<br />
<br />
Glycosylation is important because it can influence the biological activity of a protein through different mechanisms. First of all, glycosylation can affect half-life by influencing the active clearance of a protein. Certain pituitary glycoprotein hormones such as lutropin are rapidly removed from circulation by the liver if they bear a sulphated GalNAc residue. A second example is EPO, the serum half-life of which is dependent on four sialylated N-glycans (sialic acid is itself a glycan). Poorly glycosylated forms of EPO are rapidly cleared by filtration in the kidney. In addition, under-sialylated EPO is rapidly removed by hepatocytes and macrophages. Thus, increasing the degree of sialylation and glycosylation decreases the renal clearance rate, and can increase EPO in vivo activity.<br />
<br />
Glycosylation can affect the activity of a recombinant protein more directly. Rituximab, for instance,is a monoclonal antibody (mAb) used to treat non-Hodgkin<nowiki>’</nowiki>s lymphoma through targeting of B-cell CD20 antigens. Its activity can be assessed with the antibody-dependent cellular cytotoxicity (ADCC) test, which measures the ability of an engineered mAb to lyse target cells. The ADCC of two types of mAb (one of which was rituximab) was found to vary inversely according to the mAb<nowiki>’</nowiki>s glycosylation state. Rituximab was produced from Chinese hamster ovary (CHO) cells with a relatively high level of glycosylation and was found to be several-fold less cytotoxic in vitro than another anti-CD20 mAb (KM3065), which was synthesized with fewer glycan residues from a rat cell line.[http://www.ncbi.nlm.nih.gov/pubmed/16959791 Kullmann M et al,Nephrol Dial Transplant. 2006]<br />
[[Image:Glycosylation 2.jpg|thumb|left|470px|'''A protein with typical post-translational modifications and functional consequences''' Kullmann M et al,Nephrol Dial Transplant. 2006[http://www.ncbi.nlm.nih.gov/pubmed/16959791]]][[Image:Glycosylation 3.jpg|right|thumb|500px|'''Schematic view of control methods in the glycosylation pathway in a CHO cell line''' Hossler P et al, Glycobiology,2009[http://www.ncbi.nlm.nih.gov/pubmed/19494347]]]<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
'''Glycosylation and Biopharmaceutical Manufacturing:'''<br />
<br />
Protein glycosylation typically leads to a diverse array of product glycans due to multiple factors. Even with knowledge of human glycoform profiles for a particular glycoprotein, matching those attributes on the recombinant biologic is not trivial. Regulatory agencies around the world require biopharmaceutical companies to both characterize and maintain product quality attributes (including glycosylation) within defined acceptance limits. In biopharmaceutical manufacturing, the acceptance limits are based on what the cell line, upstream cell culture, harvest operation and downstream purification can support, and on the known glycoform species.<br />
<br />
Current production processes usually use microbial systems, yeast or cell lines derived from insects (SF9), mice (SP20) or hamster (CHO). Glycosylation is notably sensitive to cell growth conditions. Changes in culture pH, the availability of precursors and nutrients, and the presence or absence of various cytokines and hormones can each affect the extent of glycosylation. In addition, the presence of sialidases and other glycosidases, either secreted or released by dead cells, can cause degradation of a previously intact product.<br />
<br />
Control of this metabolic pathway can be manifested through a variety of different conditions, including the cell lines, bioprocess, and cell culture media used for protein production.[http://www.ncbi.nlm.nih.gov/pubmed/19494347 Hossler P et al, Glycobiology,2009] <br />
<br />
<br />
[[Image:Glycosylation 4.jpg|thumb|right|500px|'''Glyco-optimised biotherapeutics''' Baumeister H et al, Glycotope[http://www.glycotope.com/wp-content/uploads/documents/glycotope-article-ipt.pdf]]]<br />
<br />
<br />
<br />
'''Glycosylation in Biosimilars:'''<br />
<br />
A change is occurring in the biotechnologically derived drug industry with the impending arrival of biosimilars on the market. This is a challenge for biopharmaceutical companies where a cell line change, process changes and/or change of manufacturing site requires extensive comparability studies to prove that the molecule remains the same. Glycosylation has moved centre-stage in the development of biopharmaceutical drug products. Its influence on a protein<nowiki>’</nowiki>s characteristics has been acknowledged by regulatory requirements for the development of biosimilars that demand a high level of glycosylation-based similarity to the original product. As a consequence, glycosylated biosimilars need to be equipped with a similar pattern of glycosylation.[http://www.glycotope.com/wp-content/uploads/documents/glycotope-article-ipt.pdf Baumeister H et al, Glycotope]<br />
<br />
<br />
<br />
<br />
=Relevant Patents' Example=<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#538ED5"|'''S.No'''<br />
|align = "center" bgcolor = "#538ED5"|'''Patent/Publication No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Date of Publication'''<br />
|align = "center" bgcolor = "#538ED5"|'''Title'''<br />
|align = "center" bgcolor = "#538ED5"|'''Abstract'''<br />
|align = "center" bgcolor = "#538ED5"|'''Assignee'''<br />
|align = "center" bgcolor = "#538ED5"|'''Problem'''<br />
|align = "center" bgcolor = "#538ED5"|'''Solution'''<br />
<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|1<br />
|align = "center" bgcolor = "#DBE5F1"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6780607.PN.&OS=PN/6780607&RS=PN/6780607 US6780607B2]</u></font><br />
|align = "center" bgcolor = "#DBE5F1"|8/24/2004<br />
|align = "center" bgcolor = "#DBE5F1"|Method for cell-free protein complete post-translational modification<br />
|align = "center" bgcolor = "#DBE5F1"|The present invention relates to methods of production of the completely post-translationally modified protein by combination of cell-free protein synthesis and cell-free co-and post-translational modification. Previous cell-free protein synthesis system has only been capable of producing partially post-translationally modified protein but the present invention employs a co-and post-translational modification machinery that produces completely post-translationally modified protein.<br />
|align = "center" bgcolor = "#DBE5F1"|DreamBiogen Co., Ltd.<br />
|align = "center" bgcolor = "#DBE5F1"|For a mammalian protein to be active, it must show native post translational modifications. One way to produce proteins with native post translational modification is to culture the cells in native cell lines or modified eukaryotic hosts. This process is time consuming. Also, the available cell-free protein synthesis systems till then could not produce proteins with complete modifications. <br />
|align = "center" bgcolor = "#DBE5F1"|An advanced cell free protein synthesis system is described which works by the combination of cell free protein synthesis and cell free complete post translational modification. The system comprises ribonucleotide triphosphates, sufficient amount of co- and post-translational modification machinery such as ER/golgiaparatus or ER/Golgi apparatus/plasma membrane, or other organelles and DNA or RNA template. <br />
<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|2<br />
|align = "center"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6610516.PN.&OS=PN/6610516&RS=PN/6610516 US6610516B1]</u></font><br />
|align = "center"|8/26/2003<br />
|align = "center"|Cell culture process<br />
|align = "center"|A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding a glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and prefers an octahedral coordination geometry, and/or (c) a plasma component. In this process, the occupancy of an N-linked glycosylation site occupied only in a fraction of a glycoprotein is enhanced. Such culturing is preferably carried out at a temperature of between about 30° C. and 35° C. and/or in the presence of up to about 2 mM of a butyrate salt and/or in the presence of a cell-cycle inhibitor.<br />
|align = "center"|Genentech, Inc.<br />
|align = "center"|There is a need for increasing glycosylation site occupancy in glycoproteins having multiple glycoforms to produce glycoprotein therapeutics of consistent product quality. <br />
|align = "center"|A few modifications to the cell culture conditions have been described to increase the occupancy of a glycosylation site in productions of glycoprotein with multiple glycoforms. The modifications include addition of butyrate salt or divalent cations such as iron and manganese. Also, the cell culture temperature has been reduced to 30 - 35 degrees C instead of traditional 37 degrees C. These modifications help control the cells in Go/G1 phase of cell cycle. Glycosylated Human t-PA has been produced. <br />
<br />
|}<br />
<br />
<br />
<br />
[[Media:Glycosylation4.xls| '''Click here''' to download analyzed samples]]<br />
<br />
<br />
=Taxonomy=<br />
<mm>[[Manufacture_of_Glycosylated_Therapeutic_Proteins2.mm]]</mm><br />
<br />
'''Note:''' Taxonomy will be further populated as per detailed analysis<br />
<br />
<br />
<br />
= Assignee Analysis and IP Activity =<br />
===Top Assignees===<br />
<br />
*Roche Holding Ltd, Kirin Holdings Company Limited and Novo Nordisk are the top assignees in the field.<br />
<br />
<br />
[[Image:glycotopassi11.jpg|250px|center|frame|thumb|<center>'''Top Assignees'''</center>]]<br />
<br />
===Geographical Distribution===<br />
<br />
* '''Based on Patent No.'''<br />
<br />
[[Image:glycogeo11.jpg|250px|center|frame|thumb|<center>'''Based on relevant patents'''</center>]]<br />
<br />
''' Note''': Countries with three or lesser patents have been grouped into Others.<br />
<br />
* '''Including all family members'''<br />
[[Image:glycofam11.jpg|250px|center|frame|thumb|<center>'''Based on patent family members'''</center>]]<br />
<br />
'''Note''': Countries with 15 or lesser patents have been grouped into Others.<br />
<br />
===IP activity===<br />
* '''Patent activity based on Publication Year'''<br />
<br />
[[Image:ipactbasicpat11.jpg|250px|center|frame|thumb|<center>'''IP activity'''</center>]] <br/><br />
<br />
<br />
* '''Patent activity based on Priority Year'''<br />
[[Image:ipactpriyr11.jpg|250px|center|frame|thumb|<center>'''IP activity'''</center>]]<br />
<br/><br />
<br />
<br />
===Top Cited patents===<br />
* Patents with the maximum number of forward citations were determined and the graph shows the top 10 patents with corresponding assignees.<br />
<br />
<br />
[[Image:topcitation11.jpg|250px|center|frame|thumb|<center>'''Top cited patents'''</center>]]<br />
<br />
=Dashboard=<br />
<br />
Patents were categorized on the basis of patent focus- whether novel or modified cell lines or hosts, transgenic animals, novel enzymes, chemical/cell free methods of synthesis, and novel fermentation methods or culture conditions. Only those patents with method of manufacture of therapeutic glycoproteins as their focus have been considered in this analysis.<br /><br />
[https://www.dolcera.com/auth/dashboard/dashboard.php?workfile_id=1154 '''Click here to access dashboard''']<br />
<br />
<br />
[[Image:dashboardglyco.jpg|250px|center|frame|thumb|<center>'''Dashboard on "Production of Therapeutic Glycoproteins"'''</center>]]<br />
==Top Assignees on the basis of production methods==<br />
<br />
* '''Mammalian cell lines'''<br />
<br />
[[Image:glycomammalian11.jpg|center|1250px|thumbnail| Top assignees in mammalian cell lines category]]<br />
<br />
* '''Transgenic animals'''<br />
<br />
[[Image:glycotransgenic_n11.jpg|center|1000px|thumbnail| Top assignees in transgenic animals category]]<br />
<br />
* '''Plants'''<br />
<br />
[[Image:glycoplants_n11.jpg|center|1000px|thumbnail| Top assignees in plants category]]<br />
<br />
* '''Microorganisms'''<br />
<br />
[[Image:glycomicroorganisms11.jpg|center|1000px|thumbnail| Top assignees in microorganisms category]]<br />
<br />
* '''Enzymes'''<br />
<br />
[[Image:glycoenzymes11.jpg|center|1000px|thumbnail| Top assignees in enzymes category]]<br />
<br />
* '''Chemical/Cell free synthesis'''<br />
<br />
[[Image:glycocell-free_n11.jpg|center|1000px|thumbnail| Top assignees in chemical/cell free synthesis category]]<br />
<br />
* '''Fermentation/Culture conditions'''<br />
<br />
[[Image:glycofermentation11.jpg|center|1000px|thumbnail| Top assignees in fermentation/Culture conditions category]]<br />
<br/><br />
<br />
=Patent product mapping example=<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#538ED5"|'''S.No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Patent/ Pub No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Title'''<br />
|align = "center" bgcolor = "#538ED5"|'''Assignee/Applicant'''<br />
|align = "center" bgcolor = "#538ED5"|'''Product'''<br />
|align = "center" bgcolor = "#538ED5"|'''Product image'''<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|1<br />
|align = "center"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5459031.PN.&OS=PN/5459031&RS=PN/5459031 US5459031]</u></font><br />
|align = "center"|Methods for controlling sialic acid derivatives in recombinant glycoproteins<br />
|align = "center"|Amgen Inc.<br />
|align = "center"|<font color="#0000FF"><u>[http://www.rxlist.com/epogen-drug.htm Epogen®]</u></font><br />
|align = "center"|&nbsp;<br />
[[Image:glyco_epogen.jpg|center|150px]]<br/><br />
<br />
|}<br />
<br/><br />
<br />
<br />
<br />
----<br />
<br />
* '''Note''': The patents focusing on methods to produce glycosylated proteins, methods to alter the glycosylation pattern of the proteins, cell lines for producing glycosylated proteins or altering the glycosylation pattern, enzymes for producing glycosylated proteins or altering the glycosylation pattern were considered on target in the analysis. Patents focusing on Purification of glycoproteins or therapeutic use of a glycoprotein were considered as off target.</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Template_-_Production_Of_Therapeutic_Glycoproteins&diff=9986Template - Production Of Therapeutic Glycoproteins2011-11-21T13:31:40Z<p>Shobhit.pareek: </p>
<hr />
<div>=Objective=<br />
* The objective is to create a technology landscape report in the area of "Production of Therapeutic Glycoproteins" <br /><br />
<br />
'''Comment''' <br /><br />
The idea is to find out the innovative market players in this technology area, those are the players that are the most technologically advanced in the market place. '''Intellectual Property''' that these players hold is taken as a measure of their technological prowess in this particular area. We have used Patents to point out the innovative and technologically advanced market players.<br />
<br />
=Table of Contents=<br />
<br />
1. Introduction<br />
1.1. Glycosylation<br />
1.2. Importance of Glycosylation in Therapeutic Proteins<br />
1.3. Glycosylation and Biopharmaceutical Manufacturing<br />
1.4. Glycosylation in Biosimilars<br />
2. Search Strategy<br />
3. Sample patent analysis<br />
4. Taxonomy<br />
5. Top Citations<br />
5.1. Patent Ranking<br />
5.2. Top Cited Patents<br />
6. Patent to product mapping<br />
7. Key Findings<br />
7.1. Major Player<br />
7.2. IP Activity<br />
7.2.1. IP Activity based on Publication year<br />
7.2.2. IP Activity based on Priority year<br />
7.3. Geographical Activity<br />
7.3.1. Geographical Activity of Patents & their Family members<br />
7.4. Categorization on the basis of production methods<br />
7.4.1. Mammalian cell lines<br />
7.4.2. Transgenic Animals<br />
7.4.3. Plants<br />
7.4.4. Microorganisms<br />
7.4.5. Enzymes<br />
7.4.6. Chemical/Cell free synthesis<br />
7.4.7. Fermentation/culture conditions<br />
8. Conclusion<br />
9. References<br />
10. Appendix A: Control patents<br />
11. Appendix B: Relevant class code definitions<br />
12. Appendix C: Concept table<br />
13. Appendix D: Search strategy<br />
<br />
<br />
=Methodology=<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|'''Search Strategy'''<br />
|1. Various keywords are retrieved for conducting the search related to production of therapeutic glycoproteins from pubmed mesh, relevant patents, scientific articles and thesaurus.<br>2. The database used for patent search is Thomson innovation.<br />
|-<br />
|align = "center" bgcolor = "#4F81BD"|'''Keywords'''<br />
|Glycosylation, therapeutic proteins, monoclonal antibody, hormone, production, cell culture, fermentation etc.<br />
|-<br />
|}<br />
<br />
=Introduction=<br />
<br />
'''Glycosylation:'''<br />
<br />
Post-translational modifications – and in particular glycosylation – play a decisive role in ensuring proper protein function. Glycosylation has been found to occur in a large variety of protein classes, including – but not limited to – antibodies, protein hormones, growth factors, cytokines and vaccines. Glycosylation is the covalent attachment of a carbohydrate component to the polypeptide backbone. For some proteins glycosylation can increase solubility, influence biological half-life and/or biological activity. The two main classes of glycosidic bonds to polypeptide chains are termed N-linked and O-linked.<br><br />
* '''N-linked glycosylation''': <font color="#231F20">the glycan is linked to nitrogen in the side chain of asparagine. The oligosaccharide is attached via the amide nitrogen of an asparagine residue in the consensus sequence "asparagine — any amino acid except proline — serine/ threonine"</font><br />
* '''O-linked glycosylation''': the glycan is linked to oxygen in the side chain of mostly serine or threonine, as well as hydroxylysine. No specific consensus sequence has been identified for O-linked glycosylation.<br />
<br />
<font color="#231F20">In the case of humans, the oligosaccharides are typically composed of the following monosaccharides: mannose (Man), glucose (Glc), N-acetylglucosamine (GlcNAc), fucose (Fuc), galactose (Gal), N acetylgalactosamine (GalNAc), and sialic or neuraminic acids. The monosaccharides are linked together in a linear or branching fashion via either α- or β-glycosidic bonds between specific carbon atoms of the individual monosaccharides.</font>[http://www.ncbi.nlm.nih.gov/pubmed/17033665 Walsh G et al, Nature Biotechnology,2006]<br />
<br />
'''Importance of Glycosylation in Therapeutic Proteins:'''<br />
<br />
Many important therapeutic proteins are glycosylated including epoetin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF) and tissue plasminogen activator (t-PA). Following table lists glycosylated therapeutics currently on the market.<br />
[[Image:Glycosylation 1.jpg|thumb|center|900px| '''List of Glycosylated Therapeutic Proteins''' Hossler P et al, Glycobiology,2009 [http://www.ncbi.nlm.nih.gov/pubmed/19494347]]]<br />
<br />
Glycosylation is important because it can influence the biological activity of a protein through different mechanisms. First of all, glycosylation can affect half-life by influencing the active clearance of a protein. Certain pituitary glycoprotein hormones such as lutropin are rapidly removed from circulation by the liver if they bear a sulphated GalNAc residue. A second example is EPO, the serum half-life of which is dependent on four sialylated N-glycans (sialic acid is itself a glycan). Poorly glycosylated forms of EPO are rapidly cleared by filtration in the kidney. In addition, under-sialylated EPO is rapidly removed by hepatocytes and macrophages. Thus, increasing the degree of sialylation and glycosylation decreases the renal clearance rate, and can increase EPO in vivo activity.<br />
<br />
Glycosylation can affect the activity of a recombinant protein more directly. Rituximab, for instance,is a monoclonal antibody (mAb) used to treat non-Hodgkin<nowiki>’</nowiki>s lymphoma through targeting of B-cell CD20 antigens. Its activity can be assessed with the antibody-dependent cellular cytotoxicity (ADCC) test, which measures the ability of an engineered mAb to lyse target cells. The ADCC of two types of mAb (one of which was rituximab) was found to vary inversely according to the mAb<nowiki>’</nowiki>s glycosylation state. Rituximab was produced from Chinese hamster ovary (CHO) cells with a relatively high level of glycosylation and was found to be several-fold less cytotoxic in vitro than another anti-CD20 mAb (KM3065), which was synthesized with fewer glycan residues from a rat cell line.[http://www.ncbi.nlm.nih.gov/pubmed/16959791 Kullmann M et al,Nephrol Dial Transplant. 2006]<br />
[[Image:Glycosylation 2.jpg|thumb|left|470px|'''A protein with typical post-translational modifications and functional consequences''' Kullmann M et al,Nephrol Dial Transplant. 2006[http://www.ncbi.nlm.nih.gov/pubmed/16959791]]][[Image:Glycosylation 3.jpg|right|thumb|500px|'''Schematic view of control methods in the glycosylation pathway in a CHO cell line''' Hossler P et al, Glycobiology,2009[http://www.ncbi.nlm.nih.gov/pubmed/19494347]]]<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
'''Glycosylation and Biopharmaceutical Manufacturing:'''<br />
<br />
Protein glycosylation typically leads to a diverse array of product glycans due to multiple factors. Even with knowledge of human glycoform profiles for a particular glycoprotein, matching those attributes on the recombinant biologic is not trivial. Regulatory agencies around the world require biopharmaceutical companies to both characterize and maintain product quality attributes (including glycosylation) within defined acceptance limits. In biopharmaceutical manufacturing, the acceptance limits are based on what the cell line, upstream cell culture, harvest operation and downstream purification can support, and on the known glycoform species.<br />
<br />
Current production processes usually use microbial systems, yeast or cell lines derived from insects (SF9), mice (SP20) or hamster (CHO). Glycosylation is notably sensitive to cell growth conditions. Changes in culture pH, the availability of precursors and nutrients, and the presence or absence of various cytokines and hormones can each affect the extent of glycosylation. In addition, the presence of sialidases and other glycosidases, either secreted or released by dead cells, can cause degradation of a previously intact product.<br />
<br />
Control of this metabolic pathway can be manifested through a variety of different conditions, including the cell lines, bioprocess, and cell culture media used for protein production.[http://www.ncbi.nlm.nih.gov/pubmed/19494347 Hossler P et al, Glycobiology,2009] <br />
<br />
<br />
[[Image:Glycosylation 4.jpg|thumb|right|500px|'''Glyco-optimised biotherapeutics''' Baumeister H et al, Glycotope[http://www.glycotope.com/wp-content/uploads/documents/glycotope-article-ipt.pdf]]]<br />
<br />
<br />
<br />
'''Glycosylation in Biosimilars:'''<br />
<br />
A change is occurring in the biotechnologically derived drug industry with the impending arrival of biosimilars on the market. This is a challenge for biopharmaceutical companies where a cell line change, process changes and/or change of manufacturing site requires extensive comparability studies to prove that the molecule remains the same. Glycosylation has moved centre-stage in the development of biopharmaceutical drug products. Its influence on a protein<nowiki>’</nowiki>s characteristics has been acknowledged by regulatory requirements for the development of biosimilars that demand a high level of glycosylation-based similarity to the original product. As a consequence, glycosylated biosimilars need to be equipped with a similar pattern of glycosylation.[http://www.glycotope.com/wp-content/uploads/documents/glycotope-article-ipt.pdf Baumeister H et al, Glycotope]<br />
<br />
<br />
<br />
<br />
=Relevant Patents' Example=<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#538ED5"|'''S.No'''<br />
|align = "center" bgcolor = "#538ED5"|'''Patent/Publication No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Date of Publication'''<br />
|align = "center" bgcolor = "#538ED5"|'''Title'''<br />
|align = "center" bgcolor = "#538ED5"|'''Abstract'''<br />
|align = "center" bgcolor = "#538ED5"|'''Assignee'''<br />
|align = "center" bgcolor = "#538ED5"|'''Problem'''<br />
|align = "center" bgcolor = "#538ED5"|'''Solution'''<br />
<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|1<br />
|align = "center" bgcolor = "#DBE5F1"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6780607.PN.&OS=PN/6780607&RS=PN/6780607 US6780607B2]</u></font><br />
|align = "center" bgcolor = "#DBE5F1"|8/24/2004<br />
|align = "center" bgcolor = "#DBE5F1"|Method for cell-free protein complete post-translational modification<br />
|align = "center" bgcolor = "#DBE5F1"|The present invention relates to methods of production of the completely post-translationally modified protein by combination of cell-free protein synthesis and cell-free co-and post-translational modification. Previous cell-free protein synthesis system has only been capable of producing partially post-translationally modified protein but the present invention employs a co-and post-translational modification machinery that produces completely post-translationally modified protein.<br />
|align = "center" bgcolor = "#DBE5F1"|DreamBiogen Co., Ltd.<br />
|align = "center" bgcolor = "#DBE5F1"|For a mammalian protein to be active, it must show native post translational modifications. One way to produce proteins with native post translational modification is to culture the cells in native cell lines or modified eukaryotic hosts. This process is time consuming. Also, the available cell-free protein synthesis systems till then could not produce proteins with complete modifications. <br />
|align = "center" bgcolor = "#DBE5F1"|An advanced cell free protein synthesis system is described which works by the combination of cell free protein synthesis and cell free complete post translational modification. The system comprises ribonucleotide triphosphates, sufficient amount of co- and post-translational modification machinery such as ER/golgiaparatus or ER/Golgi apparatus/plasma membrane, or other organelles and DNA or RNA template. <br />
<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|2<br />
|align = "center"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6610516.PN.&OS=PN/6610516&RS=PN/6610516 US6610516B1]</u></font><br />
|align = "center"|8/26/2003<br />
|align = "center"|Cell culture process<br />
|align = "center"|A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding a glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and prefers an octahedral coordination geometry, and/or (c) a plasma component. In this process, the occupancy of an N-linked glycosylation site occupied only in a fraction of a glycoprotein is enhanced. Such culturing is preferably carried out at a temperature of between about 30° C. and 35° C. and/or in the presence of up to about 2 mM of a butyrate salt and/or in the presence of a cell-cycle inhibitor.<br />
|align = "center"|Genentech, Inc.<br />
|align = "center"|There is a need for increasing glycosylation site occupancy in glycoproteins having multiple glycoforms to produce glycoprotein therapeutics of consistent product quality. <br />
|align = "center"|A few modifications to the cell culture conditions have been described to increase the occupancy of a glycosylation site in productions of glycoprotein with multiple glycoforms. The modifications include addition of butyrate salt or divalent cations such as iron and manganese. Also, the cell culture temperature has been reduced to 30 - 35 degrees C instead of traditional 37 degrees C. These modifications help control the cells in Go/G1 phase of cell cycle. Glycosylated Human t-PA has been produced. <br />
<br />
|}<br />
<br />
<br />
<br />
[[Media:Glycosylation4.xls| '''Click here''' to download analyzed samples]]<br />
<br />
<br />
=Taxonomy=<br />
<mm>[[Manufacture_of_Glycosylated_Therapeutic_Proteins2.mm]]</mm><br />
<br />
'''Note:''' Taxonomy will be further populated as per detailed analysis<br />
<br />
<br />
<br />
= Assignee Analysis and IP Activity =<br />
===Top Assignees===<br />
<br />
*Roche Holding Ltd, Kirin Holdings Company Limited and Novo Nordisk are the top assignees in the field.<br />
<br />
<br />
[[Image:glycotopassi11.jpg|250px|center|frame|thumb|<center>'''Top Assignees'''</center>]]<br />
<br />
===Geographical Distribution===<br />
<br />
* '''Based on Patent No.'''<br />
<br />
[[Image:glycogeo11.jpg|250px|center|frame|thumb|<center>'''Based on relevant patents'''</center>]]<br />
<br />
''' Note''': Countries with three or lesser patents have been grouped into Others.<br />
<br />
* '''Including all family members'''<br />
[[Image:glycofam11.jpg|250px|center|frame|thumb|<center>'''Based on patent family members'''</center>]]<br />
<br />
'''Note''': Countries with 15 or lesser patents have been grouped into Others.<br />
<br />
===IP activity===<br />
* '''Patent activity based on Publication Year'''<br />
<br />
[[Image:ipactbasicpat11.jpg|250px|center|frame|thumb|<center>'''IP activity'''</center>]] <br/><br />
<br />
<br />
* '''Patent activity based on Priority Year'''<br />
[[Image:ipactpriyr11.jpg|250px|center|frame|thumb|<center>'''IP activity'''</center>]]<br />
<br/><br />
<br />
<br />
===Top Cited patents===<br />
* Patents with the maximum number of forward citations were determined and the graph shows the top 10 patents with corresponding assignees.<br />
<br />
<br />
[[Image:topcitation11.jpg|250px|center|frame|thumb|<center>'''Top cited patents'''</center>]]<br />
<br />
=Dashboard=<br />
<br />
Patents were categorized on the basis of patent focus- whether novel or modified cell lines or hosts, transgenic animals, novel enzymes, chemical/cell free methods of synthesis, and novel fermentation methods or culture conditions. Only those patents with method of manufacture of therapeutic glycoproteins as their focus have been considered in this analysis.<br /><br />
[https://www.dolcera.com/auth/dashboard/dashboard.php?workfile_id=1154 '''Click here to access dashboard''']<br />
<br />
<br />
[[Image:dashboardglyco.jpg|250px|center|frame|thumb|<center>'''Dashboard on "Production of Therapeutic Glycoproteins"'''</center>]]<br />
==Top Assignees on the basis of production methods==<br />
<br />
* '''Mammalian cell lines'''<br />
<br />
[[Image:glycomammalian11.jpg|center|1250px|thumbnail| Top assignees in mammalian cell lines category]]<br />
<br />
* '''Transgenic animals'''<br />
<br />
[[Image:glycotransgenic_n11.jpg|center|1000px|thumbnail| Top assignees in transgenic animals category]]<br />
<br />
* '''Plants'''<br />
<br />
[[Image:glycoplants_n11.jpg|center|1000px|thumbnail| Top assignees in plants category]]<br />
<br />
* '''Microorganisms'''<br />
<br />
[[Image:glycomicroorganisms11.jpg|center|1000px|thumbnail| Top assignees in microorganisms category]]<br />
<br />
* '''Enzymes'''<br />
<br />
[[Image:glycoenzymes11.jpg|center|1000px|thumbnail| Top assignees in enzymes category]]<br />
<br />
* '''Chemical/Cell free synthesis'''<br />
<br />
[[Image:glycocell-free_n11.jpg|center|1000px|thumbnail| Top assignees in chemical/cell free synthesis category]]<br />
<br />
* '''Fermentation/Culture conditions'''<br />
<br />
[[Image:glycofermentation11.jpg|center|1000px|thumbnail| Top assignees in fermentation/Culture conditions category]]<br />
<br/><br />
<br />
=Patent product mapping example=<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#538ED5"|'''S.No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Patent/ Pub No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Title'''<br />
|align = "center" bgcolor = "#538ED5"|'''Assignee/Applicant'''<br />
|align = "center" bgcolor = "#538ED5"|'''Product'''<br />
|align = "center" bgcolor = "#538ED5"|'''Product image'''<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|1<br />
|align = "center"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5459031.PN.&OS=PN/5459031&RS=PN/5459031 US5459031]</u></font><br />
|align = "center"|Methods for controlling sialic acid derivatives in recombinant glycoproteins<br />
|align = "center"|Amgen Inc.<br />
|align = "center"|<font color="#0000FF"><u>[http://www.rxlist.com/epogen-drug.htm Epogen®]</u></font><br />
|align = "center"|&nbsp;<br />
[[Image:glyco_epogen.jpg|center|150px]]<br/><br />
<br />
|}<br />
<br/><br />
<br />
<br />
<br />
----<br />
<br />
* '''Note''': The patents focusing on methods to produce glycosylated proteins, methods to alter the glycosylation pattern of the proteins, cell lines for producing glycosylated proteins or altering the glycosylation pattern, enzymes for producing glycosylated proteins or altering the glycosylation pattern were considered on target in the analysis. Patents focusing on Purification of glycoproteins or therapeutic use of a glycoprotein were considered as off target.</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Template_-_Production_Of_Therapeutic_Glycoproteins&diff=9985Template - Production Of Therapeutic Glycoproteins2011-11-21T12:57:12Z<p>Shobhit.pareek: </p>
<hr />
<div>=Objective=<br />
* The objective is to create a technology landscape report in the area of "Production of Therapeutic Glycoproteins" <br /><br />
<br />
'''Comment''' <br /><br />
The idea is to find out the innovative market players in this technology area, those are the players that are the most technologically advanced in the market place. '''Intellectual Property''' that these players hold is taken as a measure of their technological prowess in this particular area. We have used Patents to point out the innovative and technologically advanced market players.<br />
<br />
=Methodology=<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#4F81BD"|'''Search Strategy'''<br />
|1. Various keywords are retrieved for conducting the search related to production of therapeutic glycoproteins from pubmed mesh, relevant patents, scientific articles and thesaurus.<br>2. The database used for patent search is Thomson innovation.<br />
|-<br />
|align = "center" bgcolor = "#4F81BD"|'''Keywords'''<br />
|Glycosylation, therapeutic proteins, monoclonal antibody, hormone, production, cell culture, fermentation etc.<br />
|-<br />
|}<br />
<br />
=Introduction=<br />
<br />
'''Glycosylation:'''<br />
<br />
Post-translational modifications – and in particular glycosylation – play a decisive role in ensuring proper protein function. Glycosylation has been found to occur in a large variety of protein classes, including – but not limited to – antibodies, protein hormones, growth factors, cytokines and vaccines. Glycosylation is the covalent attachment of a carbohydrate component to the polypeptide backbone. For some proteins glycosylation can increase solubility, influence biological half-life and/or biological activity. The two main classes of glycosidic bonds to polypeptide chains are termed N-linked and O-linked.<br><br />
* '''N-linked glycosylation''': <font color="#231F20">the glycan is linked to nitrogen in the side chain of asparagine. The oligosaccharide is attached via the amide nitrogen of an asparagine residue in the consensus sequence "asparagine — any amino acid except proline — serine/ threonine"</font><br />
* '''O-linked glycosylation''': the glycan is linked to oxygen in the side chain of mostly serine or threonine, as well as hydroxylysine. No specific consensus sequence has been identified for O-linked glycosylation.<br />
<br />
<font color="#231F20">In the case of humans, the oligosaccharides are typically composed of the following monosaccharides: mannose (Man), glucose (Glc), N-acetylglucosamine (GlcNAc), fucose (Fuc), galactose (Gal), N acetylgalactosamine (GalNAc), and sialic or neuraminic acids. The monosaccharides are linked together in a linear or branching fashion via either α- or β-glycosidic bonds between specific carbon atoms of the individual monosaccharides.</font>[http://www.ncbi.nlm.nih.gov/pubmed/17033665 Walsh G et al, Nature Biotechnology,2006]<br />
<br />
'''Importance of Glycosylation in Therapeutic Proteins:'''<br />
<br />
Many important therapeutic proteins are glycosylated including epoetin (EPO), granulocyte macrophage colony stimulating factor (GM-CSF) and tissue plasminogen activator (t-PA). Following table lists glycosylated therapeutics currently on the market.<br />
[[Image:Glycosylation 1.jpg|thumb|center|900px| '''List of Glycosylated Therapeutic Proteins''' Hossler P et al, Glycobiology,2009 [http://www.ncbi.nlm.nih.gov/pubmed/19494347]]]<br />
<br />
Glycosylation is important because it can influence the biological activity of a protein through different mechanisms. First of all, glycosylation can affect half-life by influencing the active clearance of a protein. Certain pituitary glycoprotein hormones such as lutropin are rapidly removed from circulation by the liver if they bear a sulphated GalNAc residue. A second example is EPO, the serum half-life of which is dependent on four sialylated N-glycans (sialic acid is itself a glycan). Poorly glycosylated forms of EPO are rapidly cleared by filtration in the kidney. In addition, under-sialylated EPO is rapidly removed by hepatocytes and macrophages. Thus, increasing the degree of sialylation and glycosylation decreases the renal clearance rate, and can increase EPO in vivo activity.<br />
<br />
Glycosylation can affect the activity of a recombinant protein more directly. Rituximab, for instance,is a monoclonal antibody (mAb) used to treat non-Hodgkin<nowiki>’</nowiki>s lymphoma through targeting of B-cell CD20 antigens. Its activity can be assessed with the antibody-dependent cellular cytotoxicity (ADCC) test, which measures the ability of an engineered mAb to lyse target cells. The ADCC of two types of mAb (one of which was rituximab) was found to vary inversely according to the mAb<nowiki>’</nowiki>s glycosylation state. Rituximab was produced from Chinese hamster ovary (CHO) cells with a relatively high level of glycosylation and was found to be several-fold less cytotoxic in vitro than another anti-CD20 mAb (KM3065), which was synthesized with fewer glycan residues from a rat cell line.[http://www.ncbi.nlm.nih.gov/pubmed/16959791 Kullmann M et al,Nephrol Dial Transplant. 2006]<br />
[[Image:Glycosylation 2.jpg|thumb|left|470px|'''A protein with typical post-translational modifications and functional consequences''' Kullmann M et al,Nephrol Dial Transplant. 2006[http://www.ncbi.nlm.nih.gov/pubmed/16959791]]][[Image:Glycosylation 3.jpg|right|thumb|500px|'''Schematic view of control methods in the glycosylation pathway in a CHO cell line''' Hossler P et al, Glycobiology,2009[http://www.ncbi.nlm.nih.gov/pubmed/19494347]]]<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
<br />
'''Glycosylation and Biopharmaceutical Manufacturing:'''<br />
<br />
Protein glycosylation typically leads to a diverse array of product glycans due to multiple factors. Even with knowledge of human glycoform profiles for a particular glycoprotein, matching those attributes on the recombinant biologic is not trivial. Regulatory agencies around the world require biopharmaceutical companies to both characterize and maintain product quality attributes (including glycosylation) within defined acceptance limits. In biopharmaceutical manufacturing, the acceptance limits are based on what the cell line, upstream cell culture, harvest operation and downstream purification can support, and on the known glycoform species.<br />
<br />
Current production processes usually use microbial systems, yeast or cell lines derived from insects (SF9), mice (SP20) or hamster (CHO). Glycosylation is notably sensitive to cell growth conditions. Changes in culture pH, the availability of precursors and nutrients, and the presence or absence of various cytokines and hormones can each affect the extent of glycosylation. In addition, the presence of sialidases and other glycosidases, either secreted or released by dead cells, can cause degradation of a previously intact product.<br />
<br />
Control of this metabolic pathway can be manifested through a variety of different conditions, including the cell lines, bioprocess, and cell culture media used for protein production.[http://www.ncbi.nlm.nih.gov/pubmed/19494347 Hossler P et al, Glycobiology,2009] <br />
<br />
<br />
[[Image:Glycosylation 4.jpg|thumb|right|500px|'''Glyco-optimised biotherapeutics''' Baumeister H et al, Glycotope[http://www.glycotope.com/wp-content/uploads/documents/glycotope-article-ipt.pdf]]]<br />
<br />
<br />
<br />
'''Glycosylation in Biosimilars:'''<br />
<br />
A change is occurring in the biotechnologically derived drug industry with the impending arrival of biosimilars on the market. This is a challenge for biopharmaceutical companies where a cell line change, process changes and/or change of manufacturing site requires extensive comparability studies to prove that the molecule remains the same. Glycosylation has moved centre-stage in the development of biopharmaceutical drug products. Its influence on a protein<nowiki>’</nowiki>s characteristics has been acknowledged by regulatory requirements for the development of biosimilars that demand a high level of glycosylation-based similarity to the original product. As a consequence, glycosylated biosimilars need to be equipped with a similar pattern of glycosylation.[http://www.glycotope.com/wp-content/uploads/documents/glycotope-article-ipt.pdf Baumeister H et al, Glycotope]<br />
<br />
<br />
<br />
<br />
=Relevant Patents' Example=<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#538ED5"|'''S.No'''<br />
|align = "center" bgcolor = "#538ED5"|'''Patent/Publication No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Date of Publication'''<br />
|align = "center" bgcolor = "#538ED5"|'''Title'''<br />
|align = "center" bgcolor = "#538ED5"|'''Abstract'''<br />
|align = "center" bgcolor = "#538ED5"|'''Assignee'''<br />
|align = "center" bgcolor = "#538ED5"|'''Problem'''<br />
|align = "center" bgcolor = "#538ED5"|'''Solution'''<br />
<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|1<br />
|align = "center" bgcolor = "#DBE5F1"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6780607.PN.&OS=PN/6780607&RS=PN/6780607 US6780607B2]</u></font><br />
|align = "center" bgcolor = "#DBE5F1"|8/24/2004<br />
|align = "center" bgcolor = "#DBE5F1"|Method for cell-free protein complete post-translational modification<br />
|align = "center" bgcolor = "#DBE5F1"|The present invention relates to methods of production of the completely post-translationally modified protein by combination of cell-free protein synthesis and cell-free co-and post-translational modification. Previous cell-free protein synthesis system has only been capable of producing partially post-translationally modified protein but the present invention employs a co-and post-translational modification machinery that produces completely post-translationally modified protein.<br />
|align = "center" bgcolor = "#DBE5F1"|DreamBiogen Co., Ltd.<br />
|align = "center" bgcolor = "#DBE5F1"|For a mammalian protein to be active, it must show native post translational modifications. One way to produce proteins with native post translational modification is to culture the cells in native cell lines or modified eukaryotic hosts. This process is time consuming. Also, the available cell-free protein synthesis systems till then could not produce proteins with complete modifications. <br />
|align = "center" bgcolor = "#DBE5F1"|An advanced cell free protein synthesis system is described which works by the combination of cell free protein synthesis and cell free complete post translational modification. The system comprises ribonucleotide triphosphates, sufficient amount of co- and post-translational modification machinery such as ER/golgiaparatus or ER/Golgi apparatus/plasma membrane, or other organelles and DNA or RNA template. <br />
<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|2<br />
|align = "center"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=6610516.PN.&OS=PN/6610516&RS=PN/6610516 US6610516B1]</u></font><br />
|align = "center"|8/26/2003<br />
|align = "center"|Cell culture process<br />
|align = "center"|A glycoprotein is produced by a process comprising culturing mammalian host cells expressing nucleic acid encoding a glycoprotein in the presence of (a) a factor that modifies growth state in a cell culture, (b) a divalent metal cation that can adopt and prefers an octahedral coordination geometry, and/or (c) a plasma component. In this process, the occupancy of an N-linked glycosylation site occupied only in a fraction of a glycoprotein is enhanced. Such culturing is preferably carried out at a temperature of between about 30° C. and 35° C. and/or in the presence of up to about 2 mM of a butyrate salt and/or in the presence of a cell-cycle inhibitor.<br />
|align = "center"|Genentech, Inc.<br />
|align = "center"|There is a need for increasing glycosylation site occupancy in glycoproteins having multiple glycoforms to produce glycoprotein therapeutics of consistent product quality. <br />
|align = "center"|A few modifications to the cell culture conditions have been described to increase the occupancy of a glycosylation site in productions of glycoprotein with multiple glycoforms. The modifications include addition of butyrate salt or divalent cations such as iron and manganese. Also, the cell culture temperature has been reduced to 30 - 35 degrees C instead of traditional 37 degrees C. These modifications help control the cells in Go/G1 phase of cell cycle. Glycosylated Human t-PA has been produced. <br />
<br />
|}<br />
<br />
<br />
<br />
[[Media:Glycosylation4.xls| '''Click here''' to download analyzed samples]]<br />
<br />
<br />
=Taxonomy=<br />
<mm>[[Manufacture_of_Glycosylated_Therapeutic_Proteins2.mm]]</mm><br />
<br />
'''Note:''' Taxonomy will be further populated as per detailed analysis<br />
<br />
<br />
<br />
= Assignee Analysis and IP Activity =<br />
===Top Assignees===<br />
<br />
*Roche Holding Ltd, Kirin Holdings Company Limited and Novo Nordisk are the top assignees in the field.<br />
<br />
<br />
[[Image:glycotopassi11.jpg|250px|center|frame|thumb|<center>'''Top Assignees'''</center>]]<br />
<br />
===Geographical Distribution===<br />
<br />
* '''Based on Patent No.'''<br />
<br />
[[Image:glycogeo11.jpg|250px|center|frame|thumb|<center>'''Based on relevant patents'''</center>]]<br />
<br />
''' Note''': Countries with three or lesser patents have been grouped into Others.<br />
<br />
* '''Including all family members'''<br />
[[Image:glycofam11.jpg|250px|center|frame|thumb|<center>'''Based on patent family members'''</center>]]<br />
<br />
'''Note''': Countries with 15 or lesser patents have been grouped into Others.<br />
<br />
===IP activity===<br />
* '''Patent activity based on Publication Year'''<br />
<br />
[[Image:ipactbasicpat11.jpg|250px|center|frame|thumb|<center>'''IP activity'''</center>]] <br/><br />
<br />
<br />
* '''Patent activity based on Priority Year'''<br />
[[Image:ipactpriyr11.jpg|250px|center|frame|thumb|<center>'''IP activity'''</center>]]<br />
<br/><br />
<br />
<br />
===Top Cited patents===<br />
* Patents with the maximum number of forward citations were determined and the graph shows the top 10 patents with corresponding assignees.<br />
<br />
<br />
[[Image:topcitation11.jpg|250px|center|frame|thumb|<center>'''Top cited patents'''</center>]]<br />
<br />
=Dashboard=<br />
<br />
Patents were categorized on the basis of patent focus- whether novel or modified cell lines or hosts, transgenic animals, novel enzymes, chemical/cell free methods of synthesis, and novel fermentation methods or culture conditions. Only those patents with method of manufacture of therapeutic glycoproteins as their focus have been considered in this analysis.<br /><br />
[https://www.dolcera.com/auth/dashboard/dashboard.php?workfile_id=1154 '''Click here to access dashboard''']<br />
<br />
<br />
[[Image:dashboardglyco.jpg|250px|center|frame|thumb|<center>'''Dashboard on "Production of Therapeutic Glycoproteins"'''</center>]]<br />
==Top Assignees on the basis of production methods==<br />
<br />
* '''Mammalian cell lines'''<br />
<br />
[[Image:glycomammalian11.jpg|center|1250px|thumbnail| Top assignees in mammalian cell lines category]]<br />
<br />
* '''Transgenic animals'''<br />
<br />
[[Image:glycotransgenic_n11.jpg|center|1000px|thumbnail| Top assignees in transgenic animals category]]<br />
<br />
* '''Plants'''<br />
<br />
[[Image:glycoplants_n11.jpg|center|1000px|thumbnail| Top assignees in plants category]]<br />
<br />
* '''Microorganisms'''<br />
<br />
[[Image:glycomicroorganisms11.jpg|center|1000px|thumbnail| Top assignees in microorganisms category]]<br />
<br />
* '''Enzymes'''<br />
<br />
[[Image:glycoenzymes11.jpg|center|1000px|thumbnail| Top assignees in enzymes category]]<br />
<br />
* '''Chemical/Cell free synthesis'''<br />
<br />
[[Image:glycocell-free_n11.jpg|center|1000px|thumbnail| Top assignees in chemical/cell free synthesis category]]<br />
<br />
* '''Fermentation/Culture conditions'''<br />
<br />
[[Image:glycofermentation11.jpg|center|1000px|thumbnail| Top assignees in fermentation/Culture conditions category]]<br />
<br/><br />
<br />
=Patent product mapping example=<br />
<br />
{|border="2" cellspacing="0" cellpadding="4" width="100%"<br />
|align = "center" bgcolor = "#538ED5"|'''S.No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Patent/ Pub No.'''<br />
|align = "center" bgcolor = "#538ED5"|'''Title'''<br />
|align = "center" bgcolor = "#538ED5"|'''Assignee/Applicant'''<br />
|align = "center" bgcolor = "#538ED5"|'''Product'''<br />
|align = "center" bgcolor = "#538ED5"|'''Product image'''<br />
|-<br />
|align = "center" bgcolor = "#538ED5"|1<br />
|align = "center"|<font color="#0000FF"><u>[http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=5459031.PN.&OS=PN/5459031&RS=PN/5459031 US5459031]</u></font><br />
|align = "center"|Methods for controlling sialic acid derivatives in recombinant glycoproteins<br />
|align = "center"|Amgen Inc.<br />
|align = "center"|<font color="#0000FF"><u>[http://www.rxlist.com/epogen-drug.htm Epogen®]</u></font><br />
|align = "center"|&nbsp;<br />
[[Image:glyco_epogen.jpg|center|150px]]<br/><br />
<br />
|}<br />
<br/><br />
<br />
<br />
<br />
----<br />
<br />
* '''Note''': The patents focusing on methods to produce glycosylated proteins, methods to alter the glycosylation pattern of the proteins, cell lines for producing glycosylated proteins or altering the glycosylation pattern, enzymes for producing glycosylated proteins or altering the glycosylation pattern were considered on target in the analysis. Patents focusing on Purification of glycoproteins or therapeutic use of a glycoprotein were considered as off target.</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycotransgenic_n11.jpg&diff=9984File:Glycotransgenic n11.jpg2011-11-21T12:56:35Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycoplants_n11.jpg&diff=9983File:Glycoplants n11.jpg2011-11-21T12:56:24Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycomicroorganisms11.jpg&diff=9982File:Glycomicroorganisms11.jpg2011-11-21T12:56:14Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycomammalian11.jpg&diff=9981File:Glycomammalian11.jpg2011-11-21T12:56:04Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycofermentation11.jpg&diff=9980File:Glycofermentation11.jpg2011-11-21T12:55:54Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycoenzymes11.jpg&diff=9979File:Glycoenzymes11.jpg2011-11-21T12:55:43Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycocell-free_n11.jpg&diff=9978File:Glycocell-free n11.jpg2011-11-21T12:55:33Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glyco_epogen.jpg&diff=9977File:Glyco epogen.jpg2011-11-21T12:55:19Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Dashboardglyco.jpg&diff=9976File:Dashboardglyco.jpg2011-11-21T12:55:03Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Topcitation11.jpg&diff=9975File:Topcitation11.jpg2011-11-21T12:52:46Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Ipactpriyr11.jpg&diff=9974File:Ipactpriyr11.jpg2011-11-21T12:52:13Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Ipactbasicpat11.jpg&diff=9973File:Ipactbasicpat11.jpg2011-11-21T12:50:56Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycofam11.jpg&diff=9972File:Glycofam11.jpg2011-11-21T12:50:42Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycotopassi11.jpg&diff=9971File:Glycotopassi11.jpg2011-11-21T12:49:43Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycogeo11.jpg&diff=9970File:Glycogeo11.jpg2011-11-21T12:49:32Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Manufacture_of_Glycosylated_Therapeutic_Proteins2.mm&diff=9969File:Manufacture of Glycosylated Therapeutic Proteins2.mm2011-11-21T12:48:33Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycosylation_4.jpg&diff=9968File:Glycosylation 4.jpg2011-11-21T12:47:51Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycosylation_3.jpg&diff=9967File:Glycosylation 3.jpg2011-11-21T12:47:40Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycosylation_2.jpg&diff=9966File:Glycosylation 2.jpg2011-11-21T12:47:27Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Glycosylation_1.jpg&diff=9965File:Glycosylation 1.jpg2011-11-21T12:46:21Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=9964Main Page2011-11-21T12:40:08Z<p>Shobhit.pareek: /* Intellectual Property (IP) Services */</p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
* [[Template - Production Of Therapeutic Glycoproteins]]<br />
* [[Market Research Tools Landscape]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
* [[China ICU Ventilator Market]]<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[China ICU Ventilator Market]]<br />
* [[Patent Valuation]]<br />
* [[Automatic Faucets]]<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
* [[Landscape report for HEMT]]<br />
* [[Nanoemulsions in Foods]] <br />
* [[Variable Valve Timing - Sample]]<br />
<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=9934Main Page2011-11-03T14:24:01Z<p>Shobhit.pareek: </p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
* [[China ICU Ventilator Market]]<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[China ICU Ventilator Market]]<br />
* [[Patent Valuation]]<br />
* [[Automatic Faucets]]<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
* [[Landscape report for HEMT]]<br />
* [[Nanoemulsions in Foods]] <br />
* [[Variable Valve Timing - Sample]]<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=China_ICU_Ventilator_Market&diff=9929China ICU Ventilator Market2011-11-02T13:24:39Z<p>Shobhit.pareek: </p>
<hr />
<div>==ICU Ventilators==<br />
Intensive-care Unit (ICU) ventilators offer a wide range of breathing patterns, pressure controls, alarms and sensors. They use compressed oxygen and other gases stored in cylinders, ambient air or a mixture of both. Breathing circuits for these ventilators are double-limbed and can be quite complex. These ventilators are made for bedside use in the intensive-care units of hospitals. The key data provided by the device include:<br />
*Airway pressure (analog bar graph & numerical)<br />
*Total breath rate<br />
*Inspiratory to expiratory time ratio<br />
*Exhaled tidal volume<br />
*Exhaled minute volume<br />
*Peak flow<br />
*Inspiratory time<br />
==Market Assessment Model==<br />
The market data for ICU ventilators in China is not readily available in public domain. There are paid reports published by various market research firms in which the data is either modeled using indicators or collected through primary research methods.<br />
<br />
To arrive at the market size of ICU Ventilators in China for 2011, we have used the following methodology. We have considered only adult ICU Ventilators in this study. <br><br />
[[Image:Methodology1.png|center|700px]]<br />
'''Assumptions''': Each ICU bed will be equipped with one ventilator.<br />
<br />
==Number of ICU Beds==<br />
According to 2010 census, the total population of China is estimated as [http://blogs.wsj.com/indiarealtime/2011/04/30/china-vs-india-the-population-numbers/ 1,339,724,852]. The number of hospital beds in China as per [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS] is 22 per 10,000 population. A research paper on [http://ccforum.com/content/14/1/206 critical care medicine in mainland China] which analyzed many papers including the one from China Critical Care Clinical Trial Group (CCCCTG) estimated the % of ICU beds as total number of hospital beds as 1.8%. <br><br />
{|border="2" cellspacing="0" cellpadding="4" width="53%" align="center"<br />
|bgcolor = "#C5D9F1"|China Population, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|1,339,724,852<br />
|-<br />
|Hospital Beds per 10,000 in China<br />
|align = "right"|22<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of hospital beds<br />
|align = "right" bgcolor = "#C5D9F1"| 2,947,395<br />
|-<br />
|ICU beds as % of total hospital beds<br />
|align = "right"|1.8%<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of ICU beds in China, 2010<br />
|align = "right" bgcolor = "#C5D9F1"|'''53,053'''<br />
|-<br />
|}<br />
<br />
==Estimate of yearly growth in ICU Beds==<br />
China has taken proactive measures to control the population growth and hence it would not be a relevant indicator for growth in ICU beds. There are several factors to be considered in estimating the growth rate of ICU beds in China.<br><br />
[[Image:growth drivers2.png|center|600px]] <br><br />
*'''Large and ageing population:''' By 2025, the number of people in China aged above 65 years is estimated to reach 198 million. ''Source: US Census Bureau, International Database, July 2003''<br />
* '''Medical device industry growth:''' China medical device market has grown at a CAGR of 13.6% during 2003-2008 from $9 billion to $17 billion. ''Source: Datamonitor Report'' ; The market for Chinese medical devices in 2011 is estimated to be $23.2 billion and has grown at a CAGR of 11.1% during 2006-2011 period.'' Source: Espicom Business Intelligence''<br />
*'''Insufficient ICU beds in hospitals''' & '''Poor penetration of medical equipment:''' The % of ICU beds in the total hospital beds in China is only 1.8% as compared to 9% in US. It is hard to find an ICU unit in primary level hospitals in China. Only 23.2% of the secondary level hospitals have ICU units. In tertiary level, ICU units are present in 52.5% centers. ''Source: [http://www.criticalcarenews.com/articlePage.aspx?ArticleID=83 ''Critical Care News'']<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="61%" align="center"<br />
|align = "center" bgcolor = "#95B3D7"|'''Country'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of hospital beds per 10,000'''<br />
|align = "center" bgcolor = "#95B3D7"|'''No. of ICU beds as % of total hospital beds'''<br />
|-<br />
|align = "center"|China<br />
|align = "center"|22<br />
|align = "center"|1.8%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|USA<br />
|align = "center" bgcolor = "#C5D9F1"|31<br />
|align = "center" bgcolor = "#C5D9F1"|9.0%<br />
|-<br />
|align = "center"|France<br />
|align = "center"|73<br />
|align = "center"|2.5%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|UK<br />
|align = "center" bgcolor = "#C5D9F1"|39<br />
|align = "center" bgcolor = "#C5D9F1"|1.2%<br />
|-<br />
|align = "center"|Canada<br />
|align = "center"|34<br />
|align = "center"|3.4%<br />
|-<br />
|align = "center" bgcolor = "#C5D9F1"|Germany<br />
|align = "center" bgcolor = "#C5D9F1"|83<br />
|align = "center" bgcolor = "#C5D9F1"|4.1%<br />
|-<br />
|align = "center"|Netherlands<br />
|align = "center"|84<br />
|align = "center"|2.8%<br />
|-<br />
|}<br />
Source: [http://www.who.int/whosis/whostat/2009/en/index.html WHOSIS],[http://www.ncbi.nlm.nih.gov/pubmed/18766102 PubMed Paper]<br />
<br><br />
*'''Government policies and initiatives:''' China put forward plans in 2010 for US$124 billion to be invested in the healthcare reform programme over a three year period until 2012. Hospitals benefit from these reforms leading to faster equipment replacement and and also generating new demand for medical devices. ''Source'': [http://7economy.com/archives/10736 ''7Economy''], [http://www.globalsurance.com/blog/chinas-healthcare-reforms-progress-324520.html ''Globalsurance'']<br />
Based on the above factors the yearly growth rate in number of ICU beds is estimated to be 11.15%.<br />
<br />
==Pricing and Replacements==<br />
*The average price of an ICU ventilator in China is estimated as $ 12,500. In US, the price is between $15,000 - $ 25,000. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The average price of a disposable ICU ventilator circuit in China is estimates as $ 2.5. The price of a disposable ventilator circuit in US is between $4-$5 and that of a reusable circuit is $40-$50. ''Source: Kalorama Information Report on World Market for Mechanical ventilators''<br />
*The number of replacements of disposable circuits in a single year (2011) is estimated to be 80<br />
<br />
==Market Size Calculation==<br />
*The market for ICU Ventilators in China for 2011 is estimated to be $76 Million<br />
*The market for ICU Ventilator Circuits is about $ 12 Million<br />
*Total ICU Ventilators Market is approximately $ 88 Million in China for 2011<br />
<br><br />
{|border="2" cellspacing="0" cellpadding="4" width="60%" align="center"<br />
|Number of ICU beds in China, 2010<br />
|align = "right"|53,053<br />
|-<br />
|bgcolor = "#C5D9F1"|Yearly growth rate of ICU beds<br />
|align = "right" bgcolor = "#C5D9F1"|11.5%<br />
|-<br />
|Number of new ICU beds for 2011<br />
|align = "right"|6101<br />
|-<br />
|bgcolor = "#C5D9F1"|Market volume for ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|6101<br />
|-<br />
|Price of ICU Ventilator<br />
|align = "right"|$12,500<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$76,263,837'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total number of ICU Ventilators, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|59,154<br />
|-<br />
|Price of ICU Ventilator Circuit<br />
|align = "right"|$2.5<br />
|-<br />
|bgcolor = "#C5D9F1"|Number of replacements in a year, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|80<br />
|-<br />
|Average cost of Circuits in a year, 2011<br />
|align = "right"|$200<br />
|-<br />
|bgcolor = "#C5D9F1"|Market size of ICU Ventilator Circuits, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$11,830,842'''<br />
|-<br />
| <br />
| <br />
|-<br />
|bgcolor = "#C5D9F1"|Total market for ICU Ventilators China, 2011<br />
|align = "right" bgcolor = "#C5D9F1"|'''$88,094,679'''<br />
|-<br />
|}<br />
==Excel Work Sheet==<br />
[[Media:ICU Ventilator Market China - Work Sheet.xls]]</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:ICU_Ventilator_Market_China_-_Work_Sheet.xls&diff=9928File:ICU Ventilator Market China - Work Sheet.xls2011-11-02T13:24:19Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Growth_drivers2.png&diff=9927File:Growth drivers2.png2011-11-02T13:22:07Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Methodology1.png&diff=9926File:Methodology1.png2011-11-02T13:21:30Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=9925Main Page2011-11-02T13:19:14Z<p>Shobhit.pareek: /* Technology */</p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
* [[Nanoemulsions in Foods]] <br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Variable Valve Timing - Sample]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
* [[China ICU Ventilator Market]]<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[China ICU Ventilator Market]]<br />
* [[Patent Valuation]]<br />
* [[Automatic Faucets]]<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
* [[Landscape report for HEMT]]<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=9924Main Page2011-11-02T13:18:41Z<p>Shobhit.pareek: /* Technology */</p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
* [[Nanoemulsions in Foods]] <br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Variable Valve Timing - Sample]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
* [[China ICU Ventilator Market]]<br />
<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[Patent Valuation]]<br />
* [[Automatic Faucets]]<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
* [[Landscape report for HEMT]]<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Nanoemulsions_in_Foods&diff=9900Nanoemulsions in Foods2011-10-18T15:41:13Z<p>Shobhit.pareek: </p>
<hr />
<div>[[Image:Nano-food.jpg|[http://2020science.org/2009/03/30/'''Encapsulation''']|right|thumbnail|300px]]<br />
'''Table of Contents'''<br />
<br />
* Introduction to Nanoemulsions in Foods<br />
* Concept Table<br />
* Search strategy<br />
* Relevant class codes and definitions (IPC, US, ECLA and F-Terms)<br />
* Interactive Taxonomy<br />
* Relevant Patents<br />
* Sample patent analysis sheet<br />
* Assignee analysis and IP activity<br />
* Dashboard for assignee classification<br />
* Patent-Product Mapping<br />
* Relevant articles of Assignee Universities<br />
<br />
'''Abstract'''<br />
<br />
With the rapid technological advances, studies in the field of Food processing have been extended from micro to nano-sized (10 -9 m) particles. Food nanotechnology is rapidly emerging with several innovations in food packaging and nutraceuticals. Nano-emulsions are now being increasingly used for encapsulating bio active compounds and act as transport vehicles in functional foods and probiotic health foods.<br />
<br />
Though micro-emulsions have found a vast application in food processing, in recent years nano-emulsions are emerging out with better advantages when compared to micro-emulsions, as described below:<br />
<br />
• Size of the particle – 5 to 100 nm<br />
<br />
• Thermodynamically stable<br />
<br />
• Transparent emulsions- suitable for transparent foodstuffs like beverages<br />
<br />
• Continuous self-assembly with hydrophilic and hydrophobic portions to maintain stable emulsion state<br />
<br />
• Uncharged particles – no surface coalescence<br />
<br />
• Very small size – no sedimentation or creaming<br />
<br />
• Increased stability- increased bio availability [http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220100136207%22.PGNR.&OS=DN/20100136207&RS=DN/20100136207 Kim et al.(2010)]<br />
<br />
In general, Nano-encapsulation involves the incorporation, absorption or dispersion of bioactive compounds in small vesicles with nano (or submicron) diameters. The incorporated bioactive compounds may be protected against degradation, have improved stability and solubility (e.g., solubilizing a hydrophilic compound in hydrophobic matrices and vice versa) and therefore might increase bioavailability and delivery to cells and tissues.<br />
<br />
'''Dolcera report focuses on:'''<br />
<br />
* Finding the relevant patents encompassing the research in the fast-growing area of nano-emulsions in foods<br />
* The report highlights year-wise patent activity along with the key industrial players in the field<br />
* The different Companies have been categorized based on their position in the value chain<br />
* A comprehensible result in the form of Dolcera dashboard has been given. The dashboard links the companies in each category to their patents, hence making an interactive platform for analysis<br />
* Companies have also been segregated based on their geographical distribution<br />
* Dolcera has analyzed '''1398 patents'''. Close to 400 relevant patents related to Nano-emulsions in foods, covering around 17 countries were then analyzed in detail<br />
* Furthermore, patents have been mapped to commercially available products produced by the respective assignees and other licensees<br />
* The report also highlights different Universities and Research Institutes active in the research of the said technology area, hence pointing out opportunities for Industry tie ups.<br />
<br />
'''Some key findings:'''<br />
<br />
a. The major players in the technology:<br />
[[Image:Nanoemulsions_Top_Assignees.png|600px|center]]<br />
<br />
<p align="center">'''Top Assignees'''</p><br />
<br><br><br />
b. Country wise patent statistics:<br />
[[Image:Nanoemulsions_Geographical_dist-nano.png|center|500px]]<br />
<br><br><br />
c. Year wise IP activity:<br />
[[Image:Nanoemulsions_IP_Activity_Year_Wise.png|center|600px]]<br />
<br><br><br />
'''Class Based Taxonomy'''<br />
*This taxonomy is based on top IPC/ECLA classes related to Nanoemulsions.<br />
<br />
<mm>[[Nanofoods.mm|800px]]</mm><br />
<br><br><br />
'''Interactive Dolcera Dashboard''' <br />
* To see the interactive dashboard, [mailto:info@dolcera.com click here]<br />
[[Image:Nanoemulsions_dashboard.png|center|1000px]]<br />
<br />
<br />
==Interested in the analysis?==<br />
<p align="center"> '''Contact us for the complete report''' </p><br />
<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-425-6772<br />
|}<br />
<br><br />
<p align="center">'''Dolcera can also provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
<br />
<br />
'''Note: Now you can add an online interactive Dashboard that shows patents of Nanoemulsions in food, cited articles and literature, assignees, classifications and various other analyses to your purchase. Contact [mailto:info@dolcera.com '''info@dolcera.com] For a custom report, please write to us at: [mailto:info@dolcera.com info@dolcera.com]</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Nano-food.jpg&diff=9899File:Nano-food.jpg2011-10-18T15:39:44Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Nanoemulsions_in_Foods&diff=9898Nanoemulsions in Foods2011-10-18T15:38:53Z<p>Shobhit.pareek: </p>
<hr />
<div>[[Image:Nano-food.jpg|[http://2020science.org/2009/03/30/'''Encapsulation''']|right|thumbnail|300px]]<br />
'''Table of Contents'''<br />
<br />
* Introduction to Nanoemulsions in Foods<br />
* Concept Table<br />
* Search strategy<br />
* Relevant class codes and definitions (IPC, US, ECLA and F-Terms)<br />
* Interactive Taxonomy<br />
* Relevant Patents<br />
* Sample patent analysis sheet<br />
* Assignee analysis and IP activity<br />
* Dashboard for assignee classification<br />
* Patent-Product Mapping<br />
* Relevant articles of Assignee Universities<br />
<br />
'''Abstract'''<br />
<br />
With the rapid technological advances, studies in the field of Food processing have been extended from micro to nano-sized (10 -9 m) particles. Food nanotechnology is rapidly emerging with several innovations in food packaging and nutraceuticals. Nano-emulsions are now being increasingly used for encapsulating bio active compounds and act as transport vehicles in functional foods and probiotic health foods.<br />
<br />
Though micro-emulsions have found a vast application in food processing, in recent years nano-emulsions are emerging out with better advantages when compared to micro-emulsions, as described below:<br />
<br />
• Size of the particle – 5 to 100 nm<br />
<br />
• Thermodynamically stable<br />
<br />
• Transparent emulsions- suitable for transparent foodstuffs like beverages<br />
<br />
• Continuous self-assembly with hydrophilic and hydrophobic portions to maintain stable emulsion state<br />
<br />
• Uncharged particles – no surface coalescence<br />
<br />
• Very small size – no sedimentation or creaming<br />
<br />
• Increased stability- increased bio availability [http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220100136207%22.PGNR.&OS=DN/20100136207&RS=DN/20100136207 Kim et al.(2010)]<br />
<br />
In general, Nano-encapsulation involves the incorporation, absorption or dispersion of bioactive compounds in small vesicles with nano (or submicron) diameters. The incorporated bioactive compounds may be protected against degradation, have improved stability and solubility (e.g., solubilizing a hydrophilic compound in hydrophobic matrices and vice versa) and therefore might increase bioavailability and delivery to cells and tissues.<br />
<br />
'''Dolcera report focuses on:'''<br />
<br />
* Finding the relevant patents encompassing the research in the fast-growing area of nano-emulsions in foods<br />
* The report highlights year-wise patent activity along with the key industrial players in the field<br />
* The different Companies have been categorized based on their position in the value chain<br />
* A comprehensible result in the form of Dolcera dashboard has been given. The dashboard links the companies in each category to their patents, hence making an interactive platform for analysis<br />
* Companies have also been segregated based on their geographical distribution<br />
* Dolcera has analyzed '''1398 patents'''. Close to 400 relevant patents related to Nano-emulsions in foods, covering around 17 countries were then analyzed in detail<br />
* Furthermore, patents have been mapped to commercially available products produced by the respective assignees and other licensees<br />
* The report also highlights different Universities and Research Institutes active in the research of the said technology area, hence pointing out opportunities for Industry tie ups.<br />
<br />
'''Some key findings:'''<br />
<br />
a. The major players in the technology:<br />
[[Image:Nanoemulsions_Top_Assignees.png|600px|center]]<br />
<br />
<p align="center">'''Top Assignees'''</p><br />
<br><br><br />
b. Country wise patent statistics:<br />
[[Image:Nanoemulsions_Geographical_dist-nano.png|center|500px]]<br />
<br><br><br />
c. Year wise IP activity:<br />
[[Image:Nanoemulsions_IP_Activity_Year_Wise.png|center|600px]]<br />
<br><br><br />
'''Class Based Taxonomy'''<br />
*This taxonomy is based on top IPC/ECLA classes related to Nanoemulsions.<br />
<br />
<mm>[[Nanofoods.mm|800px]]</mm><br />
<br><br><br />
'''Interactive Dolcera Dashboard''' To see the interactive dashboard, [mailto:info@dolcera.com click here]<br />
[[Image:Nanoemulsions_dashboard.png|center|1000px]]<br />
<br />
<br />
==Interested in the analysis?==<br />
<p align="center"> '''Contact us for the complete report''' </p><br />
<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-425-6772<br />
|}<br />
<br><br />
<p align="center">'''Dolcera can also provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
<br />
<br />
'''Note: Now you can add an online interactive Dashboard that shows patents of Nanoemulsions in food, cited articles and literature, assignees, classifications and various other analyses to your purchase. Contact [mailto:info@dolcera.com '''info@dolcera.com] For a custom report, please write to us at: [mailto:info@dolcera.com info@dolcera.com]</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Nanoemulsions_in_Foods&diff=9897Nanoemulsions in Foods2011-10-18T15:35:31Z<p>Shobhit.pareek: </p>
<hr />
<div>'''Table of Contents'''<br />
<br />
* Introduction to Nanoemulsions in Foods<br />
* Concept Table<br />
* Search strategy<br />
* Relevant class codes and definitions (IPC, US, ECLA and F-Terms)<br />
* Interactive Taxonomy<br />
* Relevant Patents<br />
* Sample patent analysis sheet<br />
* Assignee analysis and IP activity<br />
* Dashboard for assignee classification<br />
* Patent-Product Mapping<br />
* Relevant articles of Assignee Universities<br />
<br />
'''Abstract'''<br />
<br />
With the rapid technological advances, studies in the field of Food processing have been extended from micro to nano-sized (10 -9 m) particles. Food nanotechnology is rapidly emerging with several innovations in food packaging and nutraceuticals. Nano-emulsions are now being increasingly used for encapsulating bio active compounds and act as transport vehicles in functional foods and probiotic health foods.<br />
<br />
Though micro-emulsions have found a vast application in food processing, in recent years nano-emulsions are emerging out with better advantages when compared to micro-emulsions, as described below:<br />
<br />
• Size of the particle – 5 to 100 nm<br />
<br />
• Thermodynamically stable<br />
<br />
• Transparent emulsions- suitable for transparent foodstuffs like beverages<br />
<br />
• Continuous self-assembly with hydrophilic and hydrophobic portions to maintain stable emulsion state<br />
<br />
• Uncharged particles – no surface coalescence<br />
<br />
• Very small size – no sedimentation or creaming<br />
<br />
• Increased stability- increased bio availability [http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220100136207%22.PGNR.&OS=DN/20100136207&RS=DN/20100136207 Kim et al.(2010)]<br />
<br />
In general, Nano-encapsulation involves the incorporation, absorption or dispersion of bioactive compounds in small vesicles with nano (or submicron) diameters. The incorporated bioactive compounds may be protected against degradation, have improved stability and solubility (e.g., solubilizing a hydrophilic compound in hydrophobic matrices and vice versa) and therefore might increase bioavailability and delivery to cells and tissues.<br />
<br />
'''Dolcera report focuses on:'''<br />
<br />
* Finding the relevant patents encompassing the research in the fast-growing area of nano-emulsions in foods<br />
* The report highlights year-wise patent activity along with the key industrial players in the field<br />
* The different Companies have been categorized based on their position in the value chain<br />
* A comprehensible result in the form of Dolcera dashboard has been given. The dashboard links the companies in each category to their patents, hence making an interactive platform for analysis<br />
* Companies have also been segregated based on their geographical distribution<br />
* Dolcera has analyzed '''1398 patents'''. Close to 400 relevant patents related to Nano-emulsions in foods, covering around 17 countries were then analyzed in detail<br />
* Furthermore, patents have been mapped to commercially available products produced by the respective assignees and other licensees<br />
* The report also highlights different Universities and Research Institutes active in the research of the said technology area, hence pointing out opportunities for Industry tie ups.<br />
<br />
'''Some key findings:'''<br />
<br />
a. The major players in the technology:<br />
[[Image:Nanoemulsions_Top_Assignees.png|600px|center]]<br />
<br />
<p align="center">'''Top Assignees'''</p><br />
<br><br><br />
b. Country wise patent statistics:<br />
[[Image:Nanoemulsions_Geographical_dist-nano.png|center|500px]]<br />
<br><br><br />
c. Year wise IP activity:<br />
[[Image:Nanoemulsions_IP_Activity_Year_Wise.png|center|600px]]<br />
<br><br><br />
'''Class Based Taxonomy'''<br />
*This taxonomy is based on top IPC/ECLA classes related to Nanoemulsions.<br />
<br />
<mm>[[Nanofoods.mm|800px]]</mm><br />
<br><br><br />
'''Interactive Dolcera Dashboard'''<br />
[[Image:Nanoemulsions_dashboard.png|center|1000px]]<br />
<br />
<br />
==Interested in the analysis?==<br />
<p align="center"> '''Contact us for the complete report''' </p><br />
<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-425-6772<br />
|}<br />
<br><br />
<p align="center">'''Dolcera can also provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
<br />
<br />
'''Note: Now you can add an online interactive Dashboard that shows patents of Nanoemulsions in food, cited articles and literature, assignees, classifications and various other analyses to your purchase. Contact [mailto:info@dolcera.com '''info@dolcera.com] For a custom report, please write to us at: [mailto:info@dolcera.com info@dolcera.com]</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Nanoemulsions_dashboard.png&diff=9896File:Nanoemulsions dashboard.png2011-10-18T15:30:03Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Nanoemulsions_IP_Activity_Year_Wise.png&diff=9895File:Nanoemulsions IP Activity Year Wise.png2011-10-18T15:28:08Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Nanoemulsions_Top_Assignees.png&diff=9894File:Nanoemulsions Top Assignees.png2011-10-18T15:25:51Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Nanoemulsions_Geographical_dist-nano.png&diff=9893File:Nanoemulsions Geographical dist-nano.png2011-10-18T15:22:12Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Nanofoods.mm&diff=9892File:Nanofoods.mm2011-10-18T15:20:38Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=9891Main Page2011-10-18T14:56:05Z<p>Shobhit.pareek: /* Intellectual Property (IP) Services */</p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
* [[Nanoemulsions in Foods]] <br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Variable Valve Timing - Sample]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
<br />
<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[Patent Valuation]]<br />
<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
* [[Landscape report for HEMT]]<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Variable_Valve_Timing&diff=9890Variable Valve Timing2011-10-17T14:22:31Z<p>Shobhit.pareek: </p>
<hr />
<div>__NOTOC__<br />
==Table of Contents==<br />
[[Image:Variable Cam Timing.jpg|right|thumb|500px|[http://www.2carpros.com/articles/how-camshaft-variable-valve-timing-works How Camshaft and Variable Valve Timing Works]]]<br />
<br />
* Introduction <br><br />
* Taxonomy <br><br />
* Top Cited Patents <br><br />
* Key Findings <br><br />
** Major Players <br><br />
** IP Activity <br><br />
*** IP Activity based on Publication year <br><br />
*** IP Activity based on Priority year <br><br />
** Geographical Activity <br><br />
*** Geographical Activity of Basic Patents & Family members<br><br />
** Major player Analysis<br><br />
*** Technology Vs Assignee Vs No. of patents <br><br />
*** Assignee Vs Publication year Vs No.of patents<br><br />
*** Assignee Vs Priority year Vs No.of patents <br><br />
*** Technology Vs Publication year Vs No.of patents<br><br />
*** Technology Vs Priority year Vs No. of patents<br><br />
** Statistical Analysis <br><br />
*** Technology Vs average citation frequency<br><br />
*** Assignee Vs average citation frequency<br><br />
* References: <br><br />
* Appendix A: Search Strategy <br><br />
* Appendix B: Sample Analysis <br><br />
<br />
<br />
<br />
<br />
== Abstract ==<br />
Variable Valve Timing is an important phenomenon in all reciprocating internal combustion engines. Valves used to control the amounts of intake air/charge thereby operating the engine without any interruption. Earlier valves open/close at a particular engine rpm. The timing of these valves is independent of engine speed. This leads to reduced engine performance. With the advent of improvements in this technology over the years this technology not only improves engine performance but also reduces harmful emissions, improves fuel economy. Hence in order to improve engine performance auto giants came up with the concept of Valve timing. FIAT first patented on this valve timing technology in 1960. But it took almost 20 years for this technology to transform into practicality. Alpha Romeo is the first car that used this technology in its cars for the first time in 1980.<br />
<br />
This present report analyses the technology of Variable Valve Timing in automobiles. It consists of a brief introduction to the technology and detailed information about its classification. By considering highly relevant patents, keywords for the patent search are generated. Different classes relating to the valve timing are identified and are used in the patent search. Detailed technology based taxonomy is also furnished. Sample of 30 relevant patents were analyzed. The report also consists of some key findings regarding top cited patents, Major players, IP activity over the years, statistical analysis of patents using forward citations etc.<br />
<br />
<font size = "3">'''Some key findings from the report include:'''</font><br />
<br />
a. The major players in the technology:<br />
[[Image:VVT_-_Top_Assignees.png|thumb|600px|center|Large automotive as well as other companies are developing capabilities in VVT]]<br />
<br />
<p align="center">'''Top Assignees'''</p><br />
<br><br><br />
b. Country wise patent statistics:<br />
[[Image:VVT - Major Countries.png|center|450px]]<br />
<br />
c. Taxonomy:<br />
<br />
===Class Based Taxonomy===<br />
*This taxonomy is based on top 50 IPC/ECLA classes related to variable valve timing technology.<br />
<mm>[[VVT - Class based taxonomy.mm|800px]]</mm><br />
<br />
===Technology Based Taxonomy===<br />
*This taxonomy is based on various components their functionality and applications of variablee valve timing.<br />
<mm>[[VVT - Technology based taxonomy.mm|800px]]</mm><br />
<br />
<br />
==Interested in the analysis?==<br />
<p align="center"> '''Contact us for the complete report''' </p><br />
<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-425-6772<br />
|}<br />
<br><br />
<p align="center">'''Dolcera can also provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
<br />
<br />
'''Note: Now you can add an online interactive Dashboard that shows VVT patents, cited articles and literature, assignees, classifications and various other analyses to your purchase. Contact [mailto:info@dolcera.com '''info@dolcera.com] For a custom report, please write to us at: [mailto:info@dolcera.com info@dolcera.com]</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:VVT_-_Technology_based_taxonomy.mm&diff=9889File:VVT - Technology based taxonomy.mm2011-10-17T14:12:13Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:VVT_-_Class_based_taxonomy.mm&diff=9888File:VVT - Class based taxonomy.mm2011-10-17T14:10:45Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:VVT_-_Major_Countries.png&diff=9887File:VVT - Major Countries.png2011-10-17T14:03:32Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:VVT_-_Top_Assignees.png&diff=9886File:VVT - Top Assignees.png2011-10-17T14:00:28Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=File:Variable_Cam_Timing.jpg&diff=9885File:Variable Cam Timing.jpg2011-10-17T13:55:21Z<p>Shobhit.pareek: </p>
<hr />
<div></div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Main_Page&diff=9884Main Page2011-10-17T13:24:26Z<p>Shobhit.pareek: /* Technology */</p>
<hr />
<div>__NOTOC__<br />
<br />
<font color="#0000FF"><font size = "4">[[#Intellectual Property (IP) Services|Intellectual Property(IP) Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Business & Information Research Services|Business and Information Research Services]]</font><br><br><br />
<font color="#0000FF"><font size = "4">[[#Dolcera Technology Platforms|Dolcera Technology Platform]]</font><br />
<br />
<br />
== Intellectual Property (IP) Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey;width:50%" valign = "top" align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey; width:50%" valign = "top" align = "left"|<br />
<br />
===Technology===<br />
|-<br />
| valign = "top" |<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Alopecia - Hair Loss]] | ([http://www.youtube.com/watch?v=jAIoyKuKQ6o Video])<br />
* [[Inflammation and cardiovascular drugs]] | ([http://www.youtube.com/watch?v=FVUFcz2dpIM Video])<br />
* [[RNAi Database sample wiki]] | ([http://www.youtube.com/watch?v=nsZLUSPn3cg Video])<br />
* [[Choline Bitartarate]]<br />
* [[Non-wovens]]<br />
* [[Pressure sensitive adhesives]] | ([http://www.youtube.com/watch?v=plP3TzjYsiQ Video])<br />
* [[Ureteral Stent]]<br />
* [[Smart Drug Delivery Systems]] | ([http://www.youtube.com/watch?v=vARe9eBFsq4 Video])<br />
* [[Silicone Hydrogel contact lens]]<br />
* [[SC Johnson]]<br />
* [[Pinene: An off flavor in mango juice]] | ([http://www.youtube.com/watch?v=P4fI1rjPjSg Video])<br />
* [[Bio-PET]]<br />
* [[Interferon For Treatment of Melanoma]]<br />
* [[Antibody against TNF]]<br />
* [[Pressure sensitive adhesives in packaging]] <br />
* [[Variable Valve Timing]] <br />
| valign = "top" |<br />
<br />
<font size = "3"><b> Landscape reports </b></font><br />
* [[Hybrid Electric Vehicle Battery System]]<br />
* [[Supply Chain RFID Applications]]<br />
* [[Insurance sector]]<br />
* [[CDMA Basics]]<br />
* [[Quality of Service on CDMA platforms]]<br />
* [[OLED - Organic Light Emitting Diode]]<br />
* [[Carbon Nanotubes (CNT)]] | ([http://www.youtube.com/watch?v=HvZqBy8XvIE Video])<br />
* [[Metallic and Ceramic construction materials]]<br />
* [[Transactional memory]]<br />
* [[Invalidation Search on a patent in the semiconductors space|Invalidation Search]]<br />
* [[Golf Club Head Landscape]]<br />
* [[Variable Valve Timing - Sample]]<br />
* [[Wind Energy]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>STN Search Reports</b></font><br />
* [[Markush Search Report]]<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard - live] <br />
** ([[Alopecia Areata Dashboard Screenshots|Screenshots only]]) <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=587 RNAi Dashboard]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Dashboard</b></font><br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=27 Automotive dashboard - live]<br />
** [[Automotive Dashboard Screenshots|Screenshots only]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 WiMAX dashboard - live] <br />
** [[WiMAX Dashboard Screenshots|Screenshots only]]<br />
* [http://www.dolcera.com/ipmapdemo/rfid_model.swf RFID dashboard]<br />
<br />
<br />
<font size = "3"><b>IP Valuation</b></font><br />
<br />
*[[Holographic Image Display]]<br />
|-<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [http://dolcera.com/client/d8r3/hairloss_map.htm Alopecia/Hair loss IPMap]<br />
* [[Markush Structure Search Sample]]<br />
<font size = "3"><b> Study: In re Bilski Impact</b></font><br />
* [[In re Bilski Impact assessed from US PAIR Information]]<br />
| valign = "top" |<br />
<br />
<font size = "3"><b>Prior Art / Invalidation / FTO Search</b></font><br />
* [[Prior Art Search Process]]<br />
* [http://www.dolcera.com/ipmapdemo/satellite_antenna/ipmap.html Satellite Antenna IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/rfid/ipmap.html RFID IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/multimodal_apps/ipmap.html Multimodal Applications IPMap]<br />
* [http://www.dolcera.com/ipmapdemo/Invalidation_US4825448.htm Invalidation Claim Chart Sample]<br />
|-<br />
|}<br />
<br />
===Clinical Trial Database===<br />
*[[Clinical Trial Database]]<br />
<br />
== Business & Information Research Services ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"| <br />
===Life Sciences and Chemistry===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Technology===<br />
|-<br />
| valign=top |<br />
* [[Cancer Vaccines - Clinical Trial Analysis]]<br />
* [[Veterinary Vaccines Market Report]]<br />
* [[Olympus Corporation- Company Profile]]<br />
* [[Rx to OTC Switch-Market Analysis]]<br />
* [[Ureteral Stent - Market Analysis]], Company Profile:[[Boston Scientific - Company Profile |Boston Scientific ]]<br />
* [[Cardiac Pacemakers]]<br />
* [[Botox - from Medical Procedure to Household Word]]<br />
* [[Diabetes products and services]]<br />
* [[Drug Metabolism]]<br />
* [[Toxicology]]<br />
* [[Osteoporosis]]<br />
* [[Oral Diabetes Drugs]]<br />
* [[Ureteral Stent]]<br />
* [[Premium Coffee Consumers Market Segmentation|Premium Coffee - Market Positioning]]<br />
* [[Dolcera's Poster on Industrial Biotechnology|Industrial biotechnology]]<br />
* [[OTC products for acne treatment]]<br />
* [[Digestive Remedies Market in India and China]]<br />
* [[OTC vs. Prescription Drugs]]<br />
* [[Vaccines Market in Western Countries]], Company Profile:[http://dolcera.com/wiki/index.php?title=GlaxoSmithKline_profile GlaxoSmithKline]<br />
* [[Gastrointestinal Endoscopy -Landscape Report]]<br />
<br />
<br />
<br />
| valign=top |<br />
* [[4G wireless technology developments]]<br />
* [[LTE]]<br />
* [[Femtocells]]<br />
* [[HDTV in the US]]<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics Innovation Explorer]<br />
* [[Web video]]<br />
* [[OLED Mobile Phones Market Research and Analysis Report]] | ([http://www.viddler.com/explore/dolcera/videos/6/ Video])<br />
* [[Samsung Company Profile]]<br />
* [[NFC Ecosystem]]<br />
* [[Virtualization]]<br />
* [[Cloud Computing]]<br />
* [[Estimation of liquid carrying vehicles in USA]]<br />
* [[A market study on Hybrid vehicles and the concept of V2G]]<br />
* [[Patent Valuation]]<br />
<br />
|-<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
<br />
===Finance===<br />
! style="background:lightgrey" valign=top width=50% align = "left"|<br />
===Others and CPG===<br />
|-<br />
| valign=top |<br />
* [[Innovative personal finance products]]<br />
* [[Life Insurance Industry in US]]<br />
| valign=top |<br />
*[[Deodorants Market Analysis: Acquisition of Sanex by Colgate]]<br />
*[[Partner in sales planning]]<br />
<br />
<br />
|}<br />
<br />
== Dolcera Technology Platforms ==<br />
{| style="border:1px solid #AAA; background:#E9E9E9;width:100%" align="center"<br />
|-<br />
| align = "top" |<br />
<br />
==== Dashboard 1.1 ====<br />
* [http://www.dolcera.com/auth/dashboarddemo/dashboard.php?workfilegroup_id=154 Demo Dashboard (Alopecia)] <br />
** [[Access details]]<br />
* [[Sample list of patent numbers]]<br />
* [http://www.dolcera.com/auth/index.php Dashboard login page]<br />
<br />
==== [[Workflow for creating a Dashboard]] ====<br />
<br />
==== IP and Products dashboard ====<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfilegroup_id=10 Alopecia areata dashboard] <br />
* [http://www.dolcera.com/ipmapdemo/stent_model.swf Stent dashboard]<br />
* [[Legal Updates Demo|Legal updates dashboard]]<br />
* [http://client.dolcera.com/dashboard/dashboard.html?workfile_id=54 4G wireless product and patent dashboard]<br />
<br />
==== Patent-pathway mapping ====<br />
* [[Inflammation and cardiovascular drugs#Interactive signaling pathways and patents|Patent-pathway mapping]]<br />
==== Sequence dashboard ====<br />
* [http://www.dolcera.com/website/demos/dna/main.html Sequence dashboard]<br />
<br />
==== Design analysis ====<br />
* [http://www.dolcera.com/website/demos/dental/main.html Dental Implant Design Analysis]<br />
<br />
==== Innovation explorer ====<br />
* [http://www.dolcera.com/ipmapdemo/innovation_explorer/innovation_explorer.html Household robotics innovation explorer]<br />
==== KPort ====<br />
* [http://dolcera.com/website/demos/kport/main.html Collaboration Portal]<br />
<br />
|-<br />
|}<br />
<br />
== Buy Dolcera Reports ==<br />
* [[Landscape report for HEMT]]<br />
<br />
<font size = "3"><b>Dolcera Offerings summary </b></font><br />
* [[Dolcera Offerings|Dolcera offerings summary]]<br />
<br />
<font size = "3"><b>[[Technology Support]] </b></font><br />
<br />
<font size = "4"><span style="color:#C41E3A">Like any of these sample reports?</span></font><br />
<p align="center"> '''These are sample reports with brief analysis''' <br><br />
'''Dolcera can provide a comprehensive report customized to your needs'''</p><br />
{|border="2" cellspacing="0" cellpadding="4" align="center" "<br />
|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com <span style="color:#0047AB">Buy the customized report from Dolcera</span>]''' <br />
|-<br />
| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]<br />
|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]<br />
|-<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]<br />
|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]<br />
|-<br />
|}<br />
<br><br />
<br />
----<br />
{| style="border:1px solid #AAA; background:#E9E9E9" align="center"<br />
|-<br />
! style="background:lightgrey" | Contact Dolcera<br />
|-<br />
! style="background:lightgrey" | Samir Raiyani<br />
|-<br />
| '''Email''': [mailto:info@dolcera.com info@dolcera.com]<br />
|-<br />
| '''Phone''': +1-650-269-7952, +91-40-2355-3493<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Business_Research&diff=9883Business Research2011-10-14T17:09:19Z<p>Shobhit.pareek: </p>
<hr />
<div>{|border="0" cellspacing="0" cellpadding="4" width="60%"<br />
|<br>'''Medical Devices'''<br>• <font color="#0000FF"><u>[https://dolcera.com/wiki/index.php?title=Cardiac_Pacemakers Cardiac Pacemakers]</u></font><br>• <font color="#0000FF"><u>[https://dolcera.com/wiki/index.php?title=Boston_Scientific_-_Company_Profile Company Profile - Boston Scientific ]</u></font><br><br>'''Pharmaceuticals'''<br>• <font color="#0000FF"><u>[http://www.dolcera.com/wiki/index.php?title=Rx_to_OTC_Switch-Market_Analysis Prescription to OTC Switch Market Analysis]</u></font><br>• <font color="#0000FF"><u>[http://www.dolcera.com/wiki/index.php?title=Veterinary_Vaccines_Market_Report Veterinary Vaccines Market Report]</u></font><br>• <font color="#0000FF"><u>[http://www.dolcera.com/wiki/index.php?title=Olympus_Corporation-_Company_Profile Company Profile - Olympus Corporation]</u></font><br><br>'''Telecommunication'''<br>• <font color="#0000FF"><u>[http://www.dolcera.com/wiki/index.php?title=OLED_Mobile_Phones_Market_Research_and_Analysis_Report OLED Mobile Phones Market Research and Analysis Report]</u></font><br />
|align = "right"|'''<br />
[[Image:Business_Research.JPG]]<br />
'''<br />
|-<br />
|}<br />
<br><br><br />
<font size = "3">'''Analytical Techniques we use'''</font><br />
<br />
{|border="0" cellspacing="2" width="60%"<br />
|• Conjoint Analysis<br>• Choice Modeling<br>• Structural Equation Modeling and Path Analysis<br>• Linear and Nonlinear Regression Techniques<br>• Cluster Analytic Techniques<br>• Bass Diffusion Modeling<br>• ANOVA, MANOVA, & ANCOVA<br>• Factor Analysis<br>• Discriminant Analysis<br />
|• Multi-Dimensional Scaling<br>• Perceptual Mapping<br>• Mixture Modeling<br>• Multiple Regression Analysis<br>• P&E Analysis<br>• TURF Analysis<br>• CPM Optimization<br>• Heat Mapping<br>• Superior Data Visualization<br />
|-<br />
|}</div>Shobhit.pareekhttps://www.dolcera.com/wiki/index.php?title=Chemical,_Oil_%26_Gas&diff=9882Chemical, Oil & Gas2011-10-14T17:08:45Z<p>Shobhit.pareek: </p>
<hr />
<div>'''Landscape Reports'''<br />
<br />
{|border="0" cellspacing="2" width="60%" valign = "top"<br />
|• <font color="#0000FF"><u>[http://www.dolcera.com/wiki/index.php?title=Pressure_sensitive_adhesives Pressure Sensitive Adhesives]</u></font><br>• <font color="#0000FF"><u>[http://www.dolcera.com/wiki/index.php?title=Dolcera%27s_Poster_on_Industrial_Biotechnology Industrial Biotechnology - BioFuels and Bio Mass ]</u></font><br>• <font color="#0000FF"><u>[http://dolcera.com/wiki/index.php?title=Alopecia_-_Hair_Loss Alopecia - Hair Loss]</u></font><br>• <font color="#0000FF"><u>[http://dolcera.com/wiki/index.php?title=Inflammation_and_cardiovascular_drugs Inflammation and Cardiovascular Drugs]</u></font><br>• <font color="#0000FF"><u>[http://dolcera.com/wiki/index.php?title=Hormone_Sensitive_Lipase Hormone Sensitive Lipase]</u></font><br>• <font color="#0000FF"><u>[http://dolcera.com/wiki/index.php?title=RNA_Interference RNA Interference]</u></font><br>• <font color="#0000FF"><u>[http://dolcera.com/wiki/index.php?title=Diabetes_products_and_services Diabetes Products and Services]</u></font><br>• <font color="#0000FF"><u>[http://dolcera.com/wiki/index.php?title=Oral_Diabetes_Drugs Oral Diabetes dDugs]</u> </font><br />
|align = "right"|'''<br />
[[Image:Landscape_report.jpg]]<br />
'''<br />
|-<br />
|}<br />
<br><br><br />
'''Dashboard'''<br />
<br />
{|valign = "top"|border="0" cellspacing="2" width="60%" <br />
|valign = "top"|• <font color="#0000FF"><u>[https://dolcera.com/wiki/index.php?title=Cardiac_Pacemakers Cardiac Pacemakers]</u></font><br>• <font color="#0000FF"><u>[https://dolcera.com/wiki/index.php?title=Boston_Scientific_-_Company_Profile Company Profile - Boston Scientific]</u></font><br>• Poster on [http://dolcera.com/wiki/index.php?title=Dolcera%27s_Poster_on_Industrial_Biotechnology <font color="#0000FF"><u>Industrial Biotechnology ]</u></font><br><br />
|align = "right"|'''<br />
[[Image:Dashboard_small.jpg]]<br />
'''<br />
|-<br />
|}<br />
<br />
'''Client References'''<br />
<br />
<font color="#0000FF"><u>[mailto:info@dolcera.com Click here]</u></font> to request client references</div>Shobhit.pareek